Moderna Inc

NASDAQ:MRNA   3:59:59 PM EDT
339.57
+6.56 (+1.97%)
5:16:15 PM EDT: $339.25 -0.32 (-0.09%)
Earnings Announcements

Moderna Inc Announces Covax Exercises Option To Purchase 176.5 Mln Additional Doses Of Moderna’S COVID-19 Vaccine For Low Income Countries

Published: 10/12/2021 13:39 GMT
Moderna Inc (MRNA) - Moderna Announces Covax Exercises Option to Purchase 176.5 Million Additional Doses of Moderna’s Covid-19 Vaccine for Low Income Countries in First Half of 2022.
Moderna Inc - Covax Has Options to Purchase an Additional 233 Million Doses in Second Half of 2022.
Moderna Inc - Requested Authorization of a 50 Μg Booster Dose From Global Regulators.
Moderna Inc - 116.5 Million Doses Are Expected to Be Delivered in Q1 of 2022 and 60 Million Doses Are Expected to Be Delivered in Q2 of 2022.
Moderna - More Than 210 Million Doses Have Now Been Purchased by Covax for Delivery to Low Income Countries, Including 34 Million Doses to Be Delivered in Q4.
Moderna -through Long-term Agreement, Unicef, Its Procurement Partners Provided Access to Up to 500 Million Doses of Moderna Covid-19 Vaccine Through 2022.
Moderna Inc - in Discussions to Allocate and Supply Covid-19 Vaccine to Self-financing Participants in Future.
Revenue is expected to be $6.49 Billion
Adjusted EPS is expected to be $9.44

Next Quarter Revenue Guidance is expected to be $7.55 Billion
Next Quarter EPS Guidance is expected to be $10.97

More details on our Analysts Page.